EU/3/16/1791
About
On 18 November 2016, orphan designation (EU/3/16/1791) was granted by the European Commission to Dr Ulrich Granzer, Germany, for a vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions (also known as DPX-Survivac) for the treatment of ovarian cancer.
The sponsorship was transferred to FGK Representative Service GmbH, Germany, in June 2020.
Key facts
Active substance |
vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions
|
Disease / condition |
Treatment of ovarian cancer
|
Date of first decision |
18/11/2016
|
Outcome |
Positive
|
EU designation number |
EU/3/16/1791
|
Sponsor's contact details
Medpace Finland Oy
Karjalankatu 2
00520 Helsinki
Helsinki-Uusimaa
Finland
Tel: +1 20 1322 9148
E-mail: z.toor@nspharma.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.